This study focuses on patients with hormone receptor-positive/HER2-negative early breast cancer, which is a type of breast cancer that tests positive for hormone receptors but negative for a protein called HER2. The treatment being studied is ribociclib (also known as Kisqali), which is taken as film-coated tablets by mouth. Ribociclib belongs to a group of medications called CDK4/6 inhibitors that help control cancer cell growth.
The purpose of this research is to evaluate how patient education and personalized coaching affect how long patients continue their treatment with ribociclib. The study will examine different approaches to supporting patients through their treatment journey and measure how these approaches impact treatment continuation.
During the study, participants will take ribociclib tablets daily and receive specialized coaching support. Throughout the treatment period, which lasts up to 36 months, patients will complete questionnaires about their quality of life and overall well-being. They will also keep a diary to track any breaks in their treatment. The study will monitor how patients manage their treatment and any side effects that may occur.
Germany 
